Psychopharmacology : (Record no. 43044)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 07740pam a22002531i 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 210705s2021 enka ob 001|0|eng|d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Terms of availability | £24.99 |
| ISBN | 9781914171444 (pbk.) : |
| 060 ## - NATIONAL LIBRARY OF MEDICINE CALL NUMBER | |
| Classification number | WM 402. |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal author | Mwebe, Herbert |
| 245 10 - TITLE STATEMENT | |
| Title | Psychopharmacology : |
| Subtitle | a mental health professional's guide to commonly used medications |
| 250 ## - EDITION | |
| Edition statement | 2nd ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | St Albans : |
| Name of producer, publisher, distributor, manufacturer | Critical Publishing, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2021. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Physical description | xiii, 314p. : |
| Other physical details | illustrations (black and white) |
| 500 ## - GENERAL NOTE | |
| General note | Previous edition: 2018. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc | Includes bibliographical references and index. |
| 505 0# - CONTENTS | |
| Contents | Table of contents -- Meet the author -- Acknowledgements -- Foreword -- Praise for the first edition -- Introduction -- The structure of this book -- Learning features -- 1 Mental illness -- 1.1 Introduction -- 1.2 Aetiology of mental illness -- 1.3 Neurodevelopmental theories -- Neurons and neurotransmitters -- 1.4 Clinical decision making in practice, and medicine management and optimisation -- Psychosocial interventions in mental health settings -- 2 Drugs used in psychoses -- 2.1 Introduction -- Severe mental illness -- Schizophrenia -- 2.2 Mechanism of action -- Biochemical theories -- Glutamate hypothesis -- Dopamine hypothesis -- Typical antipsychotics -- Atypical antipsychotics -- 2.3 Dose and administration -- Rapid tranquillisation -- Non-restrictive interventions -- Antipsychotic drugs in depot preparation -- Cytochrome P450 drug-metabolising enzymes interaction with psychotropics -- 2.4 Adverse effects and management -- Extrapyramidal side effects -- Dystonia -- Management of dystonia -- Akathisia -- Management of akathisia -- Drug-induced parkinsonism -- Management of drug-induced parkinsonism -- Tardive dyskinesia -- Management of tardive dyskinesia -- Anticholinergic drugs -- Non-extrapyramidal adverse effects of antipsychotic drugs -- Muscarinic 1 receptor block -- Cardiovascular effects -- Weight gain and mental illness -- Gender -- Socioeconomic status and level of education -- Age -- Other contributing factors to weight gain in people with mental illness -- Metabolic syndrome -- Glycaemic abnormalities as a consequence of treatment and mental illness -- Endocrine adverse effects -- Allergic and dermatological effects -- Haematological adverse effects -- Obligatory monitoring for clozapine therapy -- Clozapine alert -- Other adverse effects of clozapine.<br/>Neuroleptic malignant syndrome -- Improving physical health needs in SMI: best practice monitoring -- Behavioural change initiatives alongside routine physical health monitoring -- Lester Cardiometabolic Tool -- National Early Warning Score 2 (NEWS 2) -- QRISK®3 -- 2.5 Medication adherence in mental health settings -- 3 Drugs used in depression -- 3.1 Introduction -- ICD-11: key changes in relation to depression diagnostic criteria -- Screening for depression and anxiety in primary care settings -- Co-morbid psychiatric presentations -- Key points about assessment and management of symptoms of depression and anxiety in primary care -- 3.2 Mechanism of action -- Monoamine theory of depression -- 3.3 Dose and administration -- 3.4 Adverse effects and management -- Tricyclic antidepressants -- Adverse effects and management -- Selective serotonin reuptake inhibitors -- Adverse effects and management -- Serotonin-noradrenaline reuptake inhibitors -- Adverse effects and management -- Tetracyclic (noradrenergic and specific serotonergic antidepressants) -- Adverse effects and management -- Aminoketone (bupropion) -- Adverse effects and management -- Monoamine oxidase inhibitors -- Precautions, side effects and management -- Reversible inhibitor of monoamine oxidase type A (RIMA) -- Side effects -- Serotonin syndrome -- 3.5 Differences in therapeutic effects of antidepressants -- 4 Drugs used in dementia -- 4.1 Introduction -- Dementia assessment and diagnosis: best practice -- 4.2 Mechanism of action -- Acetylcholinesterase inhibitors -- 4.3 Dose and administration -- 4.4 Adverse effects and management -- Acetylcholinesterase inhibitors -- Cholinergic crisis -- Polypharmacy in the older person -- Antipsychotic therapy in the care of the older person -- 4.5 Memantine (NMDA receptor antagonist) -- Mechanism of action.<br/>Concomitant use of cholinesterase inhibitors and memantine -- Adverse effects and management of memantine -- 5 Drugs used in bipolar disorder -- 5.1 Introduction -- The aetiology of bipolar disorder -- Bipolar disorder clinical presentation and management -- 5.2 Mechanism of action -- 5.3 Dose and administration -- Lithium -- Valproate -- Dose and administration of valproate -- Carbamazepine -- Dose and administration of carbamazepine -- Lamotrigine -- Dose and administration of lamotrigine -- 5.4 Adverse effects, monitoring and management -- Lithium -- Adverse effects -- Lithium toxicity -- Valproate -- Carbamazepine -- Lamotrigine -- 6 Drugs used in anxiety disorders -- 6.1 Introduction -- Types of anxiety -- Generalised anxiety disorder -- Panic disorder -- Social anxiety disorder -- Agoraphobia -- Separation anxiety -- Specific phobias -- Medication-induced anxiety disorder -- 6.2 Mechanism of action -- Benzodiazepine hypnotics and anxiolytics -- Non-benzodiazepine hypnotics -- Melatonin -- Non-benzodiazepine anxiolytics -- 6.3 Dose and administration -- 6.4 Adverse effects and management -- Adverse effects of benzodiazepines -- Paradoxical reaction -- Withdrawal from benzodiazepines -- Managing withdrawal symptoms -- Risk of overdose with benzodiazepines -- Treatment in overdose -- Adverse effects of non-benzodiazepine hypnotics (Z-drugs) -- Promethazine -- Precautions and interactions (benzodiazepines and hypnotics) -- Adverse effects of non-benzodiazepine anxiolytics -- Buspirone -- Pregabalin -- Beta blockers (propranolol) -- 7 Drugs used in alcohol and substance misuse -- 7.1 Introduction -- 7.2 Most vulnerable groups to substance use disorders -- 7.3 The mesolimbic dopamine circuit as the key reward pathway component -- How does cocaine and methamphetamine use affect the functioning of the reward circuit?.<br/>7.4 Drug tolerance, dependence, addiction -- Tolerance -- Some facts about tolerance -- Dependence -- Addiction -- 7.5 The psychopharmacology of commonly used drug substances and their effects -- Club (party) drugs -- 7.6 Care planning and management of substance misuse disorders -- 7.7 Medications used to treat alcohol dependence, smoking cessation and other drug dependencies -- Drug-related deaths -- Severe mental illness and smoking cessation -- Appendix: Answers to chapter review questions and MCQs -- Chapter 1 -- Chapter 2 -- Chapter 3 -- Chapter 4 -- Chapter 5 -- Chapter 6 -- Chapter 7 -- ANSWERS TO MULTIPLE CHOICE QUESTIONS -- Study activity 1: Multiple choice questions -- Study activity 2: Multiple choice questions -- Study activity 3: Multiple choice questions -- Study activity 4: Multiple choice questions -- Study activity 5: Multiple choice questions -- Study activity 6: Multiple choice questions -- Study activity 7: Multiple choice questions -- Study activity 8: Multiple choice questions -- Study activity 9: Multiple choice questions -- Study activity 10: Multiple choice questions -- Study activity 11: Multiple choice questions -- Glossary -- References -- Index. |
| 520 ## - ABSTRACT | |
| Abstract | An updated and revised edition of this accessible best-selling text suitable for all trainee and registered health professionals who require knowledge and understanding of drugs used in the treatment of mental health conditions for prescribing or administering purposes. |
| 650 #0 - SUBJECT HEADINGS | |
| Subject term | Psychopharmacology |
| 650 #0 - SUBJECT HEADINGS | |
| Subject term | Drug therapy |
| 650 #0 - SUBJECT HEADINGS | |
| Subject term | Psychotropic drugs |
| 9 (RLIN) | 7615 |
| 650 #0 - SUBJECT HEADINGS | |
| Subject term | Mental disorders |
| 650 #0 - SUBJECT HEADINGS | |
| Subject term | Psychiatry |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Suppress in OPAC | Do not Suppress in OPAC |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Home library | Current library | Shelving location | Date acquired | Source of acquisition | Cost, normal purchase price | Full call number | Barcode | Date last seen | Cost, replacement price | Price effective from | Koha item type | Total Checkouts |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| National Library of Medicine | South London and Maudsley Trust Library | South London and Maudsley Trust Library | Shelves | 03/05/2022 | 9 | 20.00 | WM 402 MWE | 023682 | 03/05/2022 | 24.99 | 03/05/2022 | Book | |||||
| National Library of Medicine | Whittington Health Library | Whittington Health Library | Shelves | 17/02/2023 | QV 77 MWE | 00022942 | 17/02/2023 | 17/02/2023 | Book |